Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia - Full Text View

Sponsors and Collaborators:	Takeda Global Research & Development Center, Inc. Eli Lilly and Company
Information provided by:	Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier:	NCT00331487

Purpose

Efficacy Comparison of Pioglitazone to Rosiglitazone in Subjects with Type 2 Diabetes

Condition	Intervention	Phase
Diabetes Mellitus	Drug: Pioglitazone Drug: Rosiglitazone	Phase III

MedlinePlus related topics: Diabetes

Drug Information available for: Pioglitazone Pioglitazone hydrochloride Rosiglitazone Rosiglitazone Maleate Dextrose

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Pioglitazone Versus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

Further study details as provided by Takeda Global Research & Development Center, Inc.:

Primary Outcome Measures:

Change in fasting triglyceride level [ Time Frame: Final Visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Change in fasting low-density lipoprotein cholesterol. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in fasting high-density lipoprotein cholesterol. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in fasting total cholesterol. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in fasting free fatty acids. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in plasminogen activator inhibitor 1 [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in high-sensitivity C-reactive protein [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in fasting C-peptide. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Homeostasis model assessment-insulin resistance mode. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in fasting insulin. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Homeostasis model assessment-beta cell function. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in glycosylated hemoglobin. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Change in fasting plasma glucose. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Low-density lipoprotein particle concentration. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Low-density lipoprotein particle size. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
High-density lipoprotein particle size. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Very low-density lipoprotein particle size. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Apolipoprotein A-I. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Apolipoprotein B [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Lipoprotein a [ Time Frame: Final Visit ] [ Designated as safety issue: No ]
Apolipoprotein C-III. [ Time Frame: Final Visit ] [ Designated as safety issue: No ]

Enrollment:	719
Study Start Date:	September 2000
Study Completion Date:	March 2004
Primary Completion Date:	March 2004 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: Pioglitazone Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
2: Active Comparator	Drug: Rosiglitazone Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks

Detailed Description:

At least two metabolic defects contribute to the development of type 2 diabetes mellitus: relative insulin insufficiency and insulin resistance. The majority of patients with type 2 diabetes mellitus demonstrate some degree of insulin resistance. Even in the absence of hyperglycemia (high blood sugar), insulin resistance is associated with a cluster of metabolic abnormalities that increase the risk for cardiovascular disease, including dyslipidemia (unhealthy blood fat), increased expression of inflammatory markers, activation of pro-coagulants (pro-clotting), hemodynamic changes, and endothelial dysfunction.

The dyslipidemia associated with insulin resistance and type 2 diabetes mellitus is characterized by elevated triglyceride levels and decreased high-density lipoprotein (good) cholesterol levels. Although low-density lipoprotein (bad) cholesterol levels may not be significantly elevated in patients with type 2 diabetes mellitus, an increase in the proportion of small, dense low-density lipoprotein cholesterol particles of increased atherogenicity (increased formation of lipid deposits in the arteries) is observed. When compared with individuals without type 2 diabetes mellitus, the risk of cardiovascular disease is 2- to 4-fold greater in patients with type 2 diabetes mellitus, and the dyslipidemia of diabetes is an important contributor to the increased risk in this population.

By targeting the insulin resistance underlying type 2 diabetes mellitus, the thiazolidinedione class of oral antihyperglycemic medications possesses both a glucose-lowering effect and the potential to alter lipid/lipoprotein metabolism. Two thiazolidinediones are currently available for the treatment of type 2 diabetes mellitus: pioglitazone hydrochloride (ACTOS, Takeda Pharmaceuticals North America, Inc, Lincolnshire, IL) and rosiglitazone maleate (Avandia, GlaxoSmithKline, Research Triangle Park, NC).

The purpose of this study is to evaluate the triglyceride-lowering effects of pioglitazone to rosiglitazone in patients with type 2 diabetes mellitus and dyslipidemia who are not receiving any other glucose- or lipid-lowering therapies at the same time as the study medications.

Individuals who participate in this study will provide written informed consent and will be required to commit to a screening visit and approximately 7 additional visits at the study center. Study participation is anticipated to be about 39 weeks (or approximately 8 months). Multiple procedures will occur at each visit which may include fasting, blood collection, physical examinations and electrocardiograms. Participants will be required to follow a diabetic diet, self-monitor their blood glucose and maintain a study diary for the duration of the study.

Eligibility

Ages Eligible for Study:	35 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Type 2 diabetes mellitus according to the World Health Organization criteria and have diabetes-associated dyslipidemia (fasting triglycerides level between greater than or equal to 150 mg per dL and less than or equal to 600 mg per dL, and a fasting direct low-density lipoprotein cholesterol less than or equal to 130 mg per dL).
Fasting serum C-peptide greater than or equal to1 ng per
Glycosylated hemoglobin greater than or equal to 7% and less than or equal to 11% if naive to oral antihyperglycemic medications, or greater than or equal to 9.5% if previously treated with oral antihyperglycemic monotherapy

Exclusion Criteria

Investigator site personnel and their immediate families. Immediate family defined as a spouse, parent, child or sibling, whether biological or legally adopted.
Treatment with a drug within 30 days of Visit 1 that had not received regulatory approval.
Treatment within 60 days of Visit 1 with any of the following:
- insulin
- systemic glucocorticoid therapy (excluding topical and inhaled preparations)
- combination glycemic therapy (two or more oral anti-diabetes medications)
- any lipid-lowering agent (including nicotinic acid, fibrates, bile acid resin binders, statins, d thyroxine or neomycin)
- any weight loss agent (prescription or over the counter)
Pregnant, breast feeding, or intending to become pregnant during the study.
Serum creatinine greater than or equal to 176.8 μmol per L or greater than or equal to 2 plus per dipstick.
Proteinuria at Visit 1.
Alanine transaminase or aspartate transaminase greater than or equal to 1.5 times the upper limit of normal at Visit 1 or had significant clinical signs or symptoms of liver disease.
History of signs or symptoms of liver disease, such as jaundice or alanine transaminase greater than or equal to 1.5 times the upper limit of normal, while treated with any thiazolidinedione
Hemoglobin less than 10.5 g per dL for females and less than11.5 g per dL for males at Visit 1.
Clinically or biochemically based on thyroid stimulating hormone at Visit 1 hypothyroid or hyperthyroid.
History of myocardial infarction, acute cardiovascular event, or heart surgery within 6 months of Visit 1.
Functional New York Heart Association Cardiac Class III or IV disease.
Receiving renal dialysis or has had received a renal transplant.
Undergoing therapy for a malignancy other than basal cell or squamous cell skin cancer.
Clinical signs or symptoms of drug or alcohol abuse.
History of HIV infection.
Allergy to any glitazone drug.
Medical history or the presence of any clinically significant or unstable medical condition that made the patient unlikely to complete the study.
Any condition or situations that precluded adherence and completion of the protocol or a precluding ability to voluntarily give informed consent.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00331487

Show 67 Study Locations

Sponsors and Collaborators

Takeda Global Research & Development Center, Inc.

Eli Lilly and Company

Investigators

Study Director:

Alfonso Perez, MD

Takeda Global Research & Development Center, Inc.

More Information

ACTOS® Package Insert This link exits the ClinicalTrials.gov site

FDA Safety Alerts and Recalls This link exits the ClinicalTrials.gov site

Publications of Results:

Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ; GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005 Jul;28(7):1547-54.

Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2007;25(1):39-54. Erratum in: Pharmacoeconomics. 2007;25(3):237.

Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH; GLAI Study Investigators. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007 Oct;30(10):2458-64. Epub 2007 Jun 26.

Responsible Party:	Takeda Global Research & Development Center, Inc. ( Sr. VP, Clinical Science )
Study ID Numbers:	H6E-US-GLAI
Study First Received:	May 30, 2006
Last Updated:	December 11, 2008
ClinicalTrials.gov Identifier:	NCT00331487
Health Authority:	United States: Food and Drug Administration

Keywords provided by Takeda Global Research & Development Center, Inc.:

Glucose Metabolism Disorder
Dysmetabolic Syndrome
Type II Diabetes
Diabetes Mellitus

Lipoatrophic
Dyslipidemia
Drug Therapy

Study placed in the following topic categories:

Metabolic Diseases
Pioglitazone
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy

Metabolic disorder
Glucose Metabolism Disorders
Rosiglitazone
Dyslipidemias
Lipid Metabolism Disorders

Additional relevant MeSH terms:

Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009